Home

Articles from NICOX SA

Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial
 
By NICOX SA · Via GlobeNewswire · May 14, 2025
Nicox Provides Full Year 2024 Financial Results
 
By NICOX SA · Via GlobeNewswire · April 30, 2025
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial
 
By NICOX SA · Via GlobeNewswire · March 19, 2025
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update
 
By NICOX SA · Via GlobeNewswire · March 3, 2025
Nicox Announces Scientific Presentation and Conference Attendance in H1 2025
 
By NICOX SA · Via GlobeNewswire · January 28, 2025
Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights
 
By NICOX SA · Via GlobeNewswire · January 21, 2025
Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream
Attachment
By NICOX SA · Via GlobeNewswire · December 4, 2024
Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected
Attachment
By NICOX SA · Via GlobeNewswire · December 2, 2024
Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial
Attachment
By NICOX SA · Via GlobeNewswire · November 19, 2024
Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results
Income Statement
By NICOX SA · Via GlobeNewswire · October 17, 2024
Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement
Attachment
By NICOX SA · Via GlobeNewswire · September 23, 2024
Nicox Announces Approval of ZERVIATE in China
 
By NICOX SA · Via GlobeNewswire · September 18, 2024
Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board
Attachment
By NICOX SA · Via GlobeNewswire · September 4, 2024
Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470
Attachment
By NICOX SA · Via GlobeNewswire · July 25, 2024
Nicox announces attendance at upcoming conferences
Attachment
By NICOX SA · Via GlobeNewswire · July 19, 2024
Nicox Provides Second Quarter 2024 Update
 
By NICOX SA · Via GlobeNewswire · July 18, 2024
Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as Director
Attachment
By NICOX SA · Via GlobeNewswire · July 16, 2024
Nicox: 2024 Ordinary Shareholder Meeting
Attachment
By NICOX SA · Via GlobeNewswire · June 27, 2024
Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024
 
By NICOX SA · Via GlobeNewswire · May 24, 2024
Nicox’s Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024
 
By NICOX SA · Via GlobeNewswire · May 6, 2024
Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agent
 
By NICOX SA · Via GlobeNewswire · April 24, 2024
Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results
Income statement
By NICOX SA · Via GlobeNewswire · April 22, 2024